
Pro-Dex, Inc.: stock overview
Price
$65.66
November 13, 2026Market cap $210M
What Ploutos Investor adds for Pro-Dex
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Pro-Dex had revenue of $80M over the last 12 months and net income of $12M, a net margin of 15.1%. Revenue grew by 15.3% a year on average over the last 5 years. At $65.66 the shares trade at a P/E of 17.5, against a median of 14.2 over the last 5 fiscal years. It has net debt of $3.5M. It pays no dividend.
From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.
Its SEC filings- Market cap
- $210M
- 3.20M shares
- P/E
- 17.5
- Today17.5Median14.2
- Revenue, 12 months
- $80M
- +15.3% a year over 5 years
- Net margin
- 15.1%
- FY2025: 13.5%, above 79% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+20.0% a year over 2 years
Fiscal years in figures
PDEX's revenue, profit, cash flow and dividend with each year-end price, from FY2011 to FY2023, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $142M
- $210M
- Enterprise value
- $214M
- P/E 3-year median: 16.3
- 17.5
- EV / EBIT
- 16.0
- EV / Revenue
- 2.7
- P/B 3-year median: 3.9
- 4.3
- FCF yield
- 5.1%
- Earnings yield 3-year median: 6.1%
- 5.7%
Profitability
- Gross margin
- 32.5%
- Operating margin
- 16.8%
- Net margin 3-year median: 13.5%
- 15.1%
- ROIC
- 17.4%
- ROIC, 5-year average
- 12.1%
- ROE
- 26.7%
Growth
- Revenue, yearly change
- +16.5%
- EPS, yearly change
- +54.3%
- FCF, yearly change
- –
- Revenue, average a year
- +15.3%
- EPS, average a year
- +21.3%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $13M
- Total debt
- $19M
- Of which operating leases
- $2.5M
- Net debt
- $3.5M
- Net debt / EBITDA
- 0.2x
- Interest cover
- 15.4x
- Current ratio
- 4.19
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- 1.62%
- Total returned
- 1.62%
- Shares, yearly change
- -1.8%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
29.3%
Above 10% of the 161 companies in its industry, and 37% of all.
Operating margin
16.1%
Above 74% of the 186 companies in its industry, and 76% of all.
Net margin
13.5%
Above 79% of the 189 companies in its industry, and 73% of all.
ROE
21.6%
Above 91% of the 174 companies in its industry, and 86% of all.
ROA
14.4%
Above 93% of the 190 companies in its industry, and 94% of all.
Revenue growth
23.7%
Above 86% of the 186 companies in its industry, and 85% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- PRO DEX INC
- CIK
- 788920
- Exchange
- NASDAQ
- Industry (SIC)
- 3841 · Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- June 30
- Latest annual report
- June 30, 2026
- Reporting currency
- USD
- Shares
- 3.20M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with PDEX
- JNJJohnson & Johnson+0,00%Compare with PDEX
- ABBVAbbVie+0,00%Compare with PDEX
- UNHUnitedHealth+0,00%Compare with PDEX
- MRKMerck & Company+0,00%Compare with PDEX
- AMGNAmgen+0,00%Compare with PDEX
- TMOThermo Fisher Scientific+0,00%Compare with PDEX
- ABTAbbott Laboratories+0,00%Compare with PDEX
The full analysis
What do Pro-Dex's filings show?
These are Pro-Dex's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is PDEX's market cap?
Pro-Dex, Inc.'s market cap is $210M, at a price of $65.66 on November 13, 2026 and 3.20M shares.
What is PDEX's P/E?
PDEX's P/E is 17.5, on earnings per share of $3.63 over the last 12 months. The median over the last 5 fiscal years was 14.2.
How much revenue does PDEX have?
Pro-Dex had revenue of $80M over the last 12 months. Over the last 5 years it changed by +15.3% a year on average.
Does PDEX pay a dividend?
No. Pro-Dex paid no regular dividend over the last 12 months.
Where do the figures come from?
From Pro-Dex, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.